Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Robert H. Lurie Cancer Center
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT01476410
First received: October 18, 2011
Last updated: September 27, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)